Walgreen’s Scaling Back
By Zacks Investment Research on December 23, 2008 | More Posts By Zacks Investment Research | Author's Website
Walgreen Company, or Walgreen’s (WAG) reported $0.41 for the first quarter of fiscal 2009 (August fiscal year). Earnings were $0.06 below our expectations and sales came in $200 million short. The difficult retail environment negatively impacted front-end (general merchandise) same-store sales, which were flat for the quarter.
After experiencing robust same-store sales growth of 7.7% and 8.1% in fiscal 2006 and 2007, respectively, total sales in comparable stores increased 4.3% in fiscal 2008. Here, in the first quarter of fiscal 2009, same-store sales increased only 1.7%. As a result, management is reducing the organic store expansion target almost in half, from a rate of 6.6% to a range of 4.0% to 4.5% for 2010.
Our concern stems from a change in strategy that began in 2006, when management began implementing a more aggressive strategy that includes acquisitions of existing drug stores and clinics. In addition, pharmacy profits continue to be pressured from lower reimbursements on generic drugs and from Wal-Mart (WMT) entering the retail generic marketplace two years ago.
However, Walgreen is the premier national retail pharmacy chain, and our rating remains a Hold due to the stock’s low valuation.
Has Gold Just Broken Out Of Its Trend Channel?
One Reason Why The US Dollar Might Rise
Ron Paul Thinks That Fed “Oversight Is Laughable”
S&P 500 Index Is Still Overvalued
This Small Oil Exploration Company Is Ripe For A Takeover… Here’s How To Profit
Bay Street Stocks Slip Slightly Again - Canadian Commentary - 1 day ago
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary - 1 day ago
Bay Street Stocks Linger Slightly Below Unchanged Level - Canadian Commentary - 1 day ago
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary - 1 day ago
European Markets Fall, Led By Banks, Oils - European Commentary - 1 day ago


